- OPPO Find X9 series: What the company has announced about its camera system and LUMO lab initiative The Economic Times
- Oppo Find X9 Series Price in India Leaked Again; Now Expected to Launch at Higher Price Gadgets 360
- Oppo Find X9 Pro and Find…
Japan’s Teijin Limited and BioVaram (UR Advanced Therapeutics Pvt. Ltd.), a growing biotech company incubated at ASPIRE, University of Hyderabad, have entered into a strategic alliance to jointly explore opportunities for expanding the former’s portfolio of implantable medical devices and regenerative medicine products in India, while introducing BioVaram’s innovative biotech solutions to Japan.
Under the agreement, the companies will work toward obtaining regulatory approvals and commercialising Teijin’s cardiovascular repair patch, SYNFOLIUM, in India, while also expanding the reach of regenerative medicine products from Japan Tissue Engineering Co., Ltd. (J-TEC)—a Teijin Group company—across the Indian market. Mission Executive and General Manager, Regenerative Medicine & Implantable Medical Device Division, Takayuki Nakano, stated that the partnership is a major milestone in Teijin’s global expansion strategy, uniting complementary strengths to address unmet medical needs in Japan and India.
Founder and CEO of UR Advanced Therapeutics, Jaganmohan Reddy, emphasised that the collaboration accelerates BioVaram’s mission to bring India’s next-generation biotech innovations to global markets through deep research, cutting-edge technologies, and scalable manufacturing.
Together, Teijin and BioVaram will assess business feasibility, regulatory pathways, and product integration strategies to advance regenerative medicine and expand access to breakthrough healthcare solutions in both countries.
Published – November 17, 2025 07:02 pm IST
